Stent systems developer Tryton Medical has obtained the US Food and Drug Administration (FDA) premarket approval (PMA) for its Tryton Side Branch Stent to treat coronary bifurcation lesions involving large side branches.

Equipped with the Tri-ZONE technology, Tryton Side Branch Stent system is made of cobalt chromium and is deployed in the side branch artery utilising single wire balloon-expandable stent delivery system.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Compatible with any conventional drug eluting stent in the main vessel, the device comes in different diameters such as 2.5mm to 3.5mm in the side branch.

"Interventional cardiologists now have access to a stent that is specifically engineered to provide the complete lesion coverage."

Tryton Medical president and chief executive officer Shawn McCarthy said: “With this first-of-its-kind approval in the US, interventional cardiologists now have access to a stent that is specifically engineered to provide the complete lesion coverage and more predictable patient outcomes needed for the challenging anatomy of coronary bifurcation lesions.”

A randomised investigational device exemption (IDE) clinical trial conducted to evaluate the stent indicated that it has decreased the need for additional bailout stenting, during a post hoc analysis.

The study also found that the stent led to statistically lower side branch percent diameter stenosis at nine month follow up and showed comparable major adverse cardiovascular events (MACE) and myocardial infarction (MI) rates at three years.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The firm has signed a strategic distribution agreement with Cardinal Health, under which its interventional vascular business Cordis will exclusively distribute the stent in the US

Used to treat more than 12,000 patients till date, the stent is available in several countries across Europe, the Middle East and Africa.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact